Contact Information: Media Contact: Amy Cook For Carl Zeiss Meditec, Inc. 925.552.7893 Email Contact
Carl Zeiss Meditec Announces Installation of 6000th Stratus OCT
More Doctors Have Access to Powerful Tool for Diagnoses in Fight Against Sight-Threatening Diseases
| Source: Carl Zeiss Meditec, Inc.
DUBLIN, CA -- (MARKET WIRE) -- November 8, 2006 -- Carl Zeiss Meditec, Inc., one of the world's
premier medical technology companies, today announced installation of its
6,000th Stratus OCT™ system at the Cleveland Eye Clinic. Over 37,000
scans are performed daily in the United States with this revolutionary
imaging system, which is rapidly becoming the standard of care for a wide
array of ophthalmic applications.
"We purchased the Stratus OCT because of its high level of diagnostic
information, which provides us with significantly more data to help confirm
diagnoses," said William Wiley, M.D., medical director of the Cleveland Eye
Clinic. "This is clearly an exciting time for leading-edge technological
solutions such as the Stratus OCT."
According to Thomas Chester, O.D., F.A.A.O., clinical director of the
Cleveland Eye Clinic, "The system enhances our diagnostic abilities for
glaucoma patients, diabetic patients and patients with other retinal
pathologies."
The Stratus OCT, which was granted Food & Drug Administration (FDA)
clearance in January 2002, incorporates optical coherence tomography to
provide comprehensive imaging and measurement of glaucoma and retinal
disease. The system is often referred to as the "gold standard in vivo
imaging device for the posterior segment" and offers proven reproducibility
for disease management.
"We are very pleased to have the Cleveland Eye Clinic as part of the
increasing list of physicians using the Stratus OCT to help optimize their
diagnoses and therapy decisions," said Jim Taylor, president and chief
executive officer for Carl Zeiss Meditec, Inc. "This established platform
continues to offer high value with expanded capabilities that make a
difference in diagnostic imaging. As a result, our customers receive a
premium-quality system they can count on today and in the future."
The Stratus OCT is used in landmark pharmaceutical trials and studies
worldwide to help define end-points, as well as help titrate pharmaceutical
interventions for age-related macular degeneration (AMD).
Most recently, the instrument was used in a variable-dosing, open-label
uncontrolled study of 40 patients with neovascular AMD to help determine if
OCT could help guide retreatment of patients undergoing intravitreal
injections of ranibizumab (Lucentis™).
In this study, called PrONTO for Prospective OCT imaging of Neovascular AMD
patients Treated with intra-Ocular Lucentis, the Stratus OCT was used to
determine when retreatment was necessary over two years.
The visual acuity and OCT outcomes in the PrONTO study were achieved with
an average of 5.6 injections over 12 months versus 12 consecutive monthly
injections in the original ranibizumab protocol. Three injections were
given monthly to initiate therapy, then subsequent injections were
performed as increases in retinal thickness on the Stratus OCT analysis
were detected. As a result, the PrONTO study concluded that the Stratus OCT
was the single best diagnostic tool for guiding retinal pharmacotherapy
with ranibizumab.
"By using the Stratus OCT to follow patients, we were able to take
advantage of this non-invasive, quantitative and qualitative imaging
technique to give fewer injections compared with the standard monthly
dosing regimen, and for a majority of the patients, obtain visual
improvement comparable to the monthly dosing regimen," said Philip J.
Rosenfeld, M.D., Ph.D., associate professor of ophthalmology at the Bascom
Palmer Eye Institute, and the principal investigator of the PrONTO study.
About Carl Zeiss Meditec
Built on an unparalleled 160-year heritage of optical innovation, Carl
Zeiss Meditec AG (International Securities Identification Number
DE000531370) is one of the world's leading eye care solutions providers.
Its product line includes systems for the diagnosis and treatment of the
four main diseases of the eye: vision defects (refraction), cataracts,
glaucoma and retinal disorders. The company has incorporated its
technological expertise into a stream of product innovations throughout the
years, from slit lamps and fundus cameras; to the Humphrey® Field
Analyzer, recognized as the global standard for glaucoma detection and
management; to its newest applications of lasers as embodied in its
leading-edge MEL 80™ refractive laser, and innovative Stratus OCT™
device as an aid for glaucoma detection and management. Since 2005, the
company has also been present in the market for intraocular lenses and
consumables, and now covers almost the entire value chain of ophthalmic
surgery. The company is looking to continue its profitable growth in the
future. The acquisition of Carl Zeiss Surgical further supplements the
product portfolio in ophthalmic surgery and opens up additional growth
prospects in neuro and ENT surgery. Carl Zeiss Surgical is the world's
leading provider of visualization solutions in the two named fields.
Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in
Pirmasens, Germany (Carl Zeiss Meditec Systems GmbH), the USA (Carl Zeiss
Meditec Inc.), Japan (Carl Zeiss Meditec Co., Ltd.), Spain (Carl Zeiss
Meditec Iberia S.A.) and France (IOLTECH S.A., Carl Zeiss Meditec SAS). The
rapidly aging global population and other trends are expected to grow the
ophthalmic market in the long term. The company is focused on applying
innovative optical technologies to protect and enhance vision now and into
the future.
Thirty-five percent of Carl Zeiss Meditec shares are in free float. The
remaining 65 percent are held by Carl Zeiss, one of the world's leading
international groups engaged in the optical and opto-electronics industry.
All Trademarks are the property of their respected owners.